NST-628

DRUG2 trials

Sponsors

Nested Therapeutics, Inc, Nader Sanai

Conditions

GliomaGlioma, Recurrent High GradeGrade 4 Malignant GliomaMAPK Pathway Gene MutationMEK MutationMelanomaNSCLCOncology

Early Phase 1

A Study of NST-628 in Recurrent Grade 4 Glioma

Not yet recruitingNCT07784985

Nader SanaiGlioma, Recurrent High Grade, Grade 4 Malignant Glioma

Start: 2026-10-01End: 2028-07-01Target: 12Updated: 2026-09-15

Phase 1

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

RecruitingNCT06326411

Nested Therapeutics, IncGlioma, MAPK Pathway Gene Mutation, MEK Mutation +6

Start: 2024-04-09End: 2029-11-01Target: 230Updated: 2026-04-20